Stockreport

GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines [Yahoo! Finance]

Moderna, Inc.  (MRNA) 
Last moderna, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: marinabio.com/investor-relations
PDF GSK said it will pay CureVac as much as $1.56 billion to assume full control of the treatments. The companies have been working together on mRNA vaccines since 2020. [Read more]